Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial

INTRODUCTION: The objective of this work was to assess the efficacy and safety of risankizumab in psoriatic arthritis (PsA) over 76 weeks. METHODS: In this double-blind, dose-ranging phase 2 study, adults with active PsA were randomized 2:2:2:1:2 to risankizumab 150 mg at weeks 0, 4, 8, 12, and 16 (...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, Philip J., Kellner, Herbert, Morita, Akimichi, Kivitz, Alan J., Aslanyan, Stella, Padula, Steven J., Topp, Andrew S., Eldred, Ann, Behrens, Frank, Papp, Kim A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510089/
https://www.ncbi.nlm.nih.gov/pubmed/35931879
http://dx.doi.org/10.1007/s40744-022-00474-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510089/
https://www.ncbi.nlm.nih.gov/pubmed/35931879
http://dx.doi.org/10.1007/s40744-022-00474-5

Ejemplares similares